Novel antiangiogenic strategies with complementary mechanisms are needed to maximize efficacy and minimize resistance to current angiogenesis inhibitors. We explored the therapeutic potential and mechanisms of αPlGF, an antibody against placental growth factor (PlGF), a VEGF homolog, which regulates the angiogenic switch in disease, but not in health. αPlGF inhibited growth and metastasis of various tumors, including those resistant to VEGF(R) inhibitors (VEGFRIs), and enhanced the efficacy of chemotherapy and VEGFRIs. αPlGF inhibited angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct from VEGFRIs, αPlGF prevented infiltration of angiogenic macrophages and severe tumor hypoxia, and thus, did not switch on the angiogenic rescue program responsible for resistance to VEGFRIs. Moreover, it did not cause or enhance VEGFRI-related side effects. The efficacy and safety of αPlGF, its pleiotropic and complementary mechanism to VEGFRIs, and the negligible induction of an angiogenic rescue program suggest that αPlGF may constitute a novel approach for cancer treatment. © 2007 Elsevier Inc. All rights reserved.

Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels

Mazzone M.;
2007-01-01

Abstract

Novel antiangiogenic strategies with complementary mechanisms are needed to maximize efficacy and minimize resistance to current angiogenesis inhibitors. We explored the therapeutic potential and mechanisms of αPlGF, an antibody against placental growth factor (PlGF), a VEGF homolog, which regulates the angiogenic switch in disease, but not in health. αPlGF inhibited growth and metastasis of various tumors, including those resistant to VEGF(R) inhibitors (VEGFRIs), and enhanced the efficacy of chemotherapy and VEGFRIs. αPlGF inhibited angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct from VEGFRIs, αPlGF prevented infiltration of angiogenic macrophages and severe tumor hypoxia, and thus, did not switch on the angiogenic rescue program responsible for resistance to VEGFRIs. Moreover, it did not cause or enhance VEGFRI-related side effects. The efficacy and safety of αPlGF, its pleiotropic and complementary mechanism to VEGFRIs, and the negligible induction of an angiogenic rescue program suggest that αPlGF may constitute a novel approach for cancer treatment. © 2007 Elsevier Inc. All rights reserved.
2007
CELLIMMUNO
HUMDISEASE
Animals
Antibodies
Monoclonal
Antineoplastic Agents
Blood Vessels
Cell Line
Cell Movement
Drug Resistance
Neoplasm
Drug Screening Assays
Antitumor
Drug-Related Side Effects and Adverse Reactions
Health
Humans
Lymphangiogenesis
Macrophages
Mice
Neoplasm Metastasis
Neoplasms
Neovascularization
Pathologic
Placenta Growth Factor
Pregnancy Proteins
Treatment Outcome
Vascular Endothelial Growth Factor Receptor-2
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/83169
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 710
  • ???jsp.display-item.citation.isi??? 660
social impact